Advancements in Hemophilia A Therapies

EP: 1.Management Insights for Patients With Hemophilia

EP: 2.Coverage Decisions for Expensive Hemophilia Treatments

EP: 3.Impact of ICER Reports on Hemophilia Treatment Decisions

EP: 4.Enhancing Provider Access and Expertise for Rare Disease Care

EP: 5.Factors Impacting Hemophilia A Care Costs

EP: 6.Collaborative Strategies in Hemophilia A Care Cost Management

EP: 7.Strategies to Manage Medication Costs and Waste

EP: 8.Adapting to Novel Hemophilia A Treatments

EP: 9.Comprehensive Insights into Hemophilia A: Prevalence, Clinical Impact, and Economic Considerations

EP: 10.Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines

EP: 11.Hemophilia A Treatment Factors and Outcomes

EP: 12.Prophylactic Treatment Challenges and Considerations for Hemophilia A

EP: 13.Consequences of Nonadherence in Hemophilia A

Now Viewing

EP: 14.Advancements in Hemophilia A Therapies

EP: 15.Comparing Hemophilia A Therapies: Efficacy and Safety Insights

EP: 16.Real-World Insights: Factor vs Emicizumab in Hemophilia A

EP: 17.Emicizumab Dosing: Prophylaxis and Bleeding Management

EP: 18.Optimizing Hemophilia Treatment: Strategies and Adherence

EP: 19.Advancements in Hemophilia A Therapies: Altuviiio and Roctavian

EP: 20.Advancements in Hemophilia A Treatment: Fitusiran and the Evolving Landscape

This is a video synopsis/summary of an Insights featuring Steven W. Pipe, MD.

In this insightful discussion with Pipe, the focus is on evaluating current and emerging therapies for hemophilia A. The conversation delves into the classes of prophylactic treatment available, specifically highlighting 2 distinct strategies: factor replacement therapy and substitution therapy. Pipe elucidates the evolution of factor replacement products, spanning legacy standard half-life agents to Altuviiio, a high-sustained factor VIII replacement therapy with a once-weekly dosing strategy. The extended half-life agents, utilizing recombinant platforms with modifications, have shown considerable progress in reducing the treatment burden. Notably, Altuviiio maintains normal to near-normal factor VIII levels for an extended period after treatment. The discussion also introduces substitution therapy, featuring a humanized bispecific antibody with a prolonged half-life of about 30 days. This therapy mimics the action of activated factor VIII, providing steady-state hemostatic correction, administered subcutaneously for added patient convenience. The overall exploration underscores the transformative impact of these therapies, not only in altering pharmacokinetics but also in enhancing patient experience by minimizing venous access challenges and optimizing treatment efficacy.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.